nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.12.2013 | short review

Targeting AML with anti-CD33 antibodies: historical walkthrough, clinical impact, future directions

verfasst von: Spyridon Dimitrios Chondropoulos, MD, Annaliza Delastic, MD, Alexandros Spyridonidis, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

In the past years, new emerging targeted therapies against specific markers have revolutionized the field of treating malignancies. In this article, we discuss the first available agent that targets a specific molecule in acute myeloid leukemia, as well as the future possibilities that genetic research unveil.

Vorheriger Artikel T-DM1 in breast cancer therapeutics: the first drug of its generation

Nächster Artikel Brentuximab vedotin, a highly active ADC as a new therapeutic option for CD30+ lymphomas

Pressman D, Korngold L. The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies. Cancer. 1953;6(3):619–23.

Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti–CD33 calicheamicin immunoconjugate. Blood. 1999;93(11):3678–84.

Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemiain first relapse. J Clin Oncol. 2001;19(13):3244–54.

Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7(6):1490–6.

Giles F, Estey E, O’Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer. 2003;98(10):2095–104.

Tsimberidou AM, Giles FJ, Estey E, O’Brien S, Keating MJ, Kantarjian HM. The role of gemtuzumabozogamicin in acute leukaemia therapy. Br J Haematol. 2006;132(4):398–409.

Pagano L, Fianchi L, Caira M, Rutella S, Leone G. The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients. Oncogene. 2007;26(25):3679–90.

Stasi R, Evangelista ML, Buccisano F, Venditti A, Amadori S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer Treat Rev. 2008;34(1):49–60.

Petersdorf SH, Kopecky KJ, Slovak ML, et al. A phase III study of gemtuzumab ozogamicin during induction and post-consolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854–60.

10.

Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369–77.

11.

Castaigne S, Pautas C, Terré C, et al. Acute Leukemia French Association. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508–16.

12.

Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol. 2012;30(32):3924–31.

13.

van der Velden VHJ, te Marvelde JG, Hoogeveen PG, et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood. 2001;97(10):3197–320.

14.

Farhat H, Reman O, Raffoux E, et al. Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50–70-year old: a phase 1/2 study of the Acute Leukemia French Association. Am J Hematol. 2012;87(1):62–5.

15.

Mortland L, Alonzo TA, Walter RB, et al. Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy. Clin Cancer Res. 2013;19(6):1620–7.

16.

Delaunay J, Recher C, Pigneux A, et al. Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation: results of the GOELAMS AML 2006 IR study [abstract]. Blood. (ASH Annual Meeting Abstracts) 2011;118(21):37–8.

Titel: Targeting AML with anti-CD33 antibodies: historical walkthrough, clinical impact, future directions
verfasst von: Spyridon Dimitrios Chondropoulos, MD
Annaliza Delastic, MD
Alexandros Spyridonidis, MD
Publikationsdatum: 01.12.2013
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 4/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-013-0121-9

Springer Medizin Österreich

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

ASCO 2013: new developments in lung cancer

ASCO annual meeting 2013: head and neck cancer

Transfusion-associated graft-versus-host disease: an update

Targeted delivery of anticancer agents using antibodies as vectors

ASCO 2013: news in early-stage and advanced breast cancer

Recent developments in the palliative treatment of breast cancer: ASCO 2013